🇺🇸

US SEC Filing Intelligence

· daily

Significant Contract Modifications ($10M+) — September 26, 2026

This digest covers a single, large civilian contract modification from NASA to Universities Space Research Association (USRA) valued at $248.4 million, representing the entire aggregate obligation for the period. The contract is a cost-plus-fixed-fee award for academic mission services at NASA Ames Research Center, with a neutral signal strength of 6/10 and low pricing risk. Key investment implications include stable but capped profit margins for USRA, a looming expiration date in November 2024 that creates renewal uncertainty, and partial performance with $143.6 million already outlayed. The absence of defense-related contracts and the sole civilian focus highlight NASA's sustained investment in R&D services, but the lack of follow-on awards or options beyond 2024 is a critical watch item.

1 total filings
· daily

Contract Deobligations Alert — September 26, 2026

This digest covers a single contract deobligation alert totaling $248.4 million, entirely from NASA and civilian in nature, with no defense-related awards. The dominant signal is neutral, centered on a cost-plus-fixed-fee contract to Universities Space Research Association (USRA) for academic mission services at Ames Research Center, which provides stable but capped margins and faces near-term expiration in November 2024. The highest-conviction signal is the renewal uncertainty, as $143.6 million has already been outlayed, leaving the remaining $104.8 million at risk without a follow-on award. Key risks include contract concentration on a single nonprofit entity and budget dependency on NASA's R&D allocations, while no bullish or bearish signals were identified in this period.

1 total filings
· daily

Contract Option Exercises — September 26, 2026

The sole contract in this digest is a $248.4M cost-plus-fixed-fee award from NASA Ames Research Center to the nonprofit Universities Space Research Association (USRA) for academic mission services, representing 100% civilian agency spend with no defense exposure. The contract, which began in June 2016 and ends November 30, 2024, carries a neutral signal strength of 6/10 and materiality of 5/10, reflecting stable but capped-margin revenue for USRA. The dominant theme is NASA's sustained investment in R&D services (NAICS 541712), though the contract's impending expiration creates near-term renewal uncertainty. The highest-conviction signal is the low pricing risk (cost-plus-fixed-fee) offset by the lack of options beyond 2024, making re-compete risk the key watch item. Investors should monitor NASA's FY2025 budget cycle and any follow-on award announcements for USRA's academic mission support at Ames Research Center.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — September 26, 2026

This digest covers a single mega contract ($100M+) from September 26, 2026, totaling $248.4M, with zero defense-related awards—entirely civilian (NASA). The dominant theme is NASA’s sustained investment in academic R&D services, led by Universities Space Research Association (USRA) under a cost-plus-fixed-fee contract. The highest-conviction signal is the contract’s impending November 2024 expiration, creating renewal uncertainty for USRA’s ~$29M annual revenue stream. Key risk: no options beyond that date, with $143.6M already outlayed, signaling partial performance and potential revenue gap.

1 total filings
· daily

High-Value Federal Grants ($5M+) — September 26, 2026

This digest covers a single high-value civilian grant of $248.4M from NASA to Universities Space Research Association (USRA) for academic mission services, with no defense-related contracts. The contract is cost-plus-fixed-fee, indicating low profit volatility but capped upside, and it expires in November 2024, posing renewal uncertainty. The highest-conviction signal is neutral, reflecting stable near-term revenue for USRA but limited growth catalyst. Key risk is the impending expiration without clear follow-on awards, while the civilian R&D sector remains stable under NASA budget trends.

1 total filings
· daily

General Federal Contracts — September 26, 2026

This digest covers a single $248.4M civilian contract awarded to Universities Space Research Association (USRA) by NASA Ames Research Center, with no defense-related exposure. The cost-plus-fixed-fee pricing structure provides stable but capped margins (6-10%), and the contract's impending expiration on November 30, 2024 introduces material renewal risk. The dominant theme is NASA's continued investment in academic R&D services, but the lack of follow-on awards or options creates a near-term revenue cliff for USRA. Key watch items include NASA's budget trajectory for academic mission support and any re-compete announcements before the contract end date.

1 total filings
· daily

All NASA Contracts — September 26, 2026

The sole contract in this digest is a $248.4M cost-plus-fixed-fee award from NASA to Universities Space Research Association (USRA) for academic mission services at Ames Research Center. As a civilian agency contract with no defense linkage, it reflects stable NASA R&D investment but carries renewal risk due to its November 2024 expiration. The neutral signal and low pricing risk suggest predictable but capped profit margins for USRA, with $143.6M already outlayed. Key watch items include the upcoming re-compete decision and NASA's budget trajectory for academic mission support.

1 total filings
· daily

Biotech Small-Cap Approvals — September 25, 2026

The September 25, 2026 approval period delivered zero NMEs, zero biosimilars, and zero label expansions, yielding three neutral 'Other' approvals classified as FALLBACK. All three approvals—DEFLAZACORT (Hikma), LANREOTIDE ACETATE (Amneal), and ROCURONIUM BROMIDE (Baxter Healthcare)—are generic or biosimilar-like entries with no disclosed peak sales estimates, exclusivity, or pricing power data. No dominant therapeutic area theme emerges, as the drugs span corticosteroids, somatostatin analogs, and neuromuscular blockers. The highest-conviction signal is the absence of any NME or Breakthrough Therapy designation, indicating a low-catalyst period for small-cap biotech investors. Key watch item: the lack of commercial detail (NOT_DISCLOSED across all entries) limits actionable investment conclusions, making this a period to monitor for future label expansions or originator responses rather than trade on today's approvals.

3 total filings
· daily

Big Pharma Approvals — September 25, 2026

This digest covers a single approval from September 25, 2026: a label expansion for Merck Sharp Dohme's sotatercept-csrk (WINREVAIR), classified as a FALLBACK approval with a bullish signal. There were no NME, biosimilar, or standard label expansion approvals in this period, making this a low-volume but directionally positive event for Merck. The approval reinforces Merck's position in the pulmonary arterial hypertension (PAH) space, though the lack of disclosed commercial details (peak sales, exclusivity, pricing power) limits conviction. The key risk is the absence of context on whether this expansion meaningfully broadens the addressable patient population or faces competitive headwinds from other PAH therapies.

1 total filings
· daily

Orphan Drug Approvals — September 25, 2026

During the single-day period of September 25, 2026, the FDA recorded only one orphan drug approval: a label expansion for Merck Sharp & Dohme’s sotatercept-csrk (Winrevair), classified as a 'fallback' type and providing a moderately bullish investment signal. No new molecular entities (NMEs), biosimilars, or additional label expansions were approved, resulting in a historically sparse approval day with zero high-value catalyst events. The sole approval does not cluster with any dominant therapeutic area theme beyond the orphan drug context, and the lack of NME activity offers no fresh pipeline breadth for the sector. Key risk remains the absence of commercial disclosure—peak sales, exclusivity status, and pricing power for this label expansion are all listed as undisclosed—limiting the depth of actionable intelligence for investors.

1 total filings
· daily

New Drug Approvals (Original) — September 25, 2026

The September 25, 2026 approval period recorded zero NMEs, zero biosimilars, and zero label expansions, with all three approvals classified as 'Other' (generic/biosimilar-like entries under FALLBACK designations). The period lacks a dominant therapeutic area theme, as the three approvals—DEFLAZACORT (Hikma), LANREOTIDE ACETATE (Amneal), and ROCURONIUM BROMIDE (Baxter Healthcare)—span distinct markets (corticosteroid, somatostatin analog, neuromuscular blocker). There is no highest-conviction bullish or bearish signal; all three carry neutral signals with moderate strength and materiality. The key watch item is the absence of NME approvals, which signals a quiet catalyst period for innovative biotech sponsors, though the generic/biosimilar entries may pressure originator pricing in niche markets.

3 total filings
· daily

VA Healthcare & Services Contracts — September 25, 2026

The digest covers a single, massive $1.2B civilian healthcare contract awarded by the Department of Veterans Affairs (VA) to TriWest Healthcare Alliance Corp on September 23, 2026. This is a non-defense award, representing a significant VA commitment to healthcare services. The contract carries a bullish signal with high materiality, but the lack of pricing details, competition context, and revenue estimates introduces execution and budget risks. The dominant theme is VA healthcare outsourcing, with TriWest as the sole beneficiary in this period.

1 total filings
· daily

New Federal Contractors — September 25, 2026

The September 25, 2026 new contractor stream totals $2.59 billion across four awards, all from civilian agencies (0% defense), signaling a pronounced shift toward civilian IT and healthcare services. TriWest Healthcare Alliance's $1.20 billion VA contract dominates the stream (46% of total value) and is the sole bullish signal, while the remaining three contracts—Maximus Federal Services ($911M), Guidehouse Digital ($258M), and General Dynamics IT ($218M)—are all completed or expiring, representing legacy revenue with no follow-on visibility. The highest-conviction signal is TriWest's VA award, which underscores durable demand for veteran healthcare administration, but the concentration of expiring contracts across Maximus, Guidehouse, and GDIT creates a bearish overhang for revenue sustainability. Key risk: the VA contract's competitive moat and pricing structure remain undisclosed, while the other three contracts have all passed their performance periods, offering no forward revenue support.

4 total filings
· daily

Significant Contract Modifications ($10M+) — September 25, 2026

This digest covers four significant government contract modifications and awards totaling $2.59 billion, all from civilian agencies (0% defense-related), signaling a strong but isolated civilian-sector procurement pulse. The dominant theme is Census Bureau IT and support services, with two contracts (MAXIMUS FEDERAL SERVICES, $911M; GUIDEHOUSE DIGITAL, $258M) tied to the 2020 Census lifecycle. The highest-conviction signal is the $1.2B sole-source award to TRIWEST HEALTHCARE ALLIANCE CORP from the VA, which is bullish for the company but lacks competitive context. A key risk is that three of the four contracts (MAXIMUS, GUIDEHOUSE, GENERAL DYNAMICS IT) have already expired, creating revenue gaps and no immediate follow-on visibility, which tempers the bullish narrative.

4 total filings
· daily

Contract Deobligations Alert — September 25, 2026

This digest covers $2.59 billion in total obligations across four civilian contracts, with zero defense-related awards, underscoring a heavy tilt toward civilian agency spending, particularly the Department of Commerce (Census Bureau) and Department of Veterans Affairs. The highest-conviction signal is the $1.2 billion sole-source award to TriWest Healthcare Alliance Corp from the VA, which is bullish for TriWest but raises concentration risk for the VA. A key risk is that three of the four contracts (Maximus, Guidehouse Digital, General Dynamics IT) have already expired, creating revenue gaps for those contractors unless follow-on work is awarded. The dominant theme is large-scale civilian IT and healthcare support services, with cost-plus pricing structures reducing profit risk for contractors but limiting upside.

4 total filings
· daily

Contract Option Exercises — September 25, 2026

This digest covers $2.59 billion in total obligations across four contract actions, all from civilian agencies (0% defense-related), signaling a significant concentration of federal spending in non-defense IT and administrative services. The dominant agency is the Department of Commerce, specifically the Census Bureau, which accounts for $1.17 billion (45%) of the total value. The highest-conviction signal is a $1.2 billion option exercise for TriWest Healthcare Alliance Corp. by the Department of Veterans Affairs, representing a massive, durable revenue stream for a healthcare contractor. A key risk is that three of the four contracts are either expired or nearing expiration, creating material revenue gaps for Maximus, Guidehouse Digital, and General Dynamics IT unless follow-on awards materialize. The overall signal is neutral, with one bullish outlier in healthcare administration.

4 total filings
· daily

Federal IT & Cybersecurity Contracts — September 25, 2026

This digest covers two federal IT contracts totaling $475.5 million, both awarded to civilian agencies (Department of Commerce and GSA), with zero defense-related awards. The dominant theme is mature, cost-plus IT infrastructure and enterprise operations support for large civilian agencies, with Guidehouse Digital’s $257.6 million Census Bureau contract (ending March 2024) representing the highest-conviction signal due to its imminent revenue gap. General Dynamics Information Technology’s $217.9 million Army National Guard contract has already expired, offering no current revenue contribution. The neutral signal strength (5.0/10) across both awards reflects the lack of growth catalysts, policy tailwinds, or competitive moats. Key risk: Guidehouse Digital faces a near-term revenue cliff unless a follow-on contract is secured before March 31, 2024.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — September 25, 2026

This digest covers $2.59 billion in aggregate contract obligations across four awards, all from civilian agencies (0% defense-related), signaling a concentrated civilian-sector spending theme. The dominant agency is the Department of Commerce (Census Bureau), accounting for $1.17 billion across two contracts (MAXIMUS FEDERAL SERVICES and GUIDEHOUSE DIGITAL). The highest-conviction signal is the $1.2 billion TRIWEST HEALTHCARE ALLIANCE CORP award from the VA, a large sole-source-like civilian healthcare contract with bullish implications for VA outsourcing. A key risk is that three of the four contracts are expired or nearing expiration (MAXIMUS, GUIDEHOUSE, GENERAL DYNAMICS), creating revenue gaps for those contractors unless follow-on awards materialize. Average signal strength is moderate at 5.8/10, reflecting the preponderance of neutral, completed contracts.

4 total filings
· daily

High-Value Federal Grants ($5M+) — September 25, 2026

This digest covers $2.59 billion in obligations across four contracts, all awarded to civilian agencies (0% defense-related), signaling a heavy concentration in Department of Commerce (Census Bureau) IT and support services. The highest-conviction signal is a $1.2 billion sole-source award to TRIWEST HEALTHCARE ALLIANCE CORP from the Department of Veterans Affairs, representing a massive, durable revenue stream. However, three of the four contracts are expired or nearing expiration, creating significant revenue uncertainty for MAXIMUS FEDERAL SERVICES, INC., Guidehouse Digital LLC, and General Dynamics Information Technology, Inc. The key risk is the lack of follow-on contracts for these legacy awards, which could create near-term revenue gaps for the affected contractors.

4 total filings
· daily

General Federal Contracts — September 25, 2026

This digest covers $2.59 billion in federal contracts awarded between 2014 and 2026, with zero defense-related awards—all are civilian, dominated by the Department of Commerce (Census Bureau) and the Department of Veterans Affairs. The highest-conviction signal is TriWest Healthcare Alliance Corp.'s $1.2 billion VA contract, a bullish award that underscores strong demand for healthcare administration services. However, three of four contracts are expired or nearing expiration, creating significant revenue uncertainty for MAXIMUS, Guidehouse Digital, and General Dynamics IT. Key risk: the $911 million MAXIMUS Census contract ended in 2021 with no follow-on, pressuring future earnings.

4 total filings